113 related articles for article (PubMed ID: 15893317)
1. Exploring blocker binding to a homology model of the open hERG K+ channel using docking and molecular dynamics methods.
Osterberg F; Aqvist J
FEBS Lett; 2005 May; 579(13):2939-44. PubMed ID: 15893317
[TBL] [Abstract][Full Text] [Related]
2. The low-potency, voltage-dependent HERG blocker propafenone--molecular determinants and drug trapping.
Witchel HJ; Dempsey CE; Sessions RB; Perry M; Milnes JT; Hancox JC; Mitcheson JS
Mol Pharmacol; 2004 Nov; 66(5):1201-12. PubMed ID: 15308760
[TBL] [Abstract][Full Text] [Related]
3. A two-state homology model of the hERG K+ channel: application to ligand binding.
Rajamani R; Tounge BA; Li J; Reynolds CH
Bioorg Med Chem Lett; 2005 Mar; 15(6):1737-41. PubMed ID: 15745831
[TBL] [Abstract][Full Text] [Related]
4. Interaction simulation of hERG K+ channel with its specific BeKm-1 peptide: insights into the selectivity of molecular recognition.
Yi H; Cao Z; Yin S; Dai C; Wu Y; Li W
J Proteome Res; 2007 Feb; 6(2):611-20. PubMed ID: 17269718
[TBL] [Abstract][Full Text] [Related]
5. Structural determinants for high-affinity block of hERG potassium channels.
Mitcheson J; Perry M; Stansfeld P; Sanguinetti MC; Witchel H; Hancox J
Novartis Found Symp; 2005; 266():136-50; discussion 150-8. PubMed ID: 16050266
[TBL] [Abstract][Full Text] [Related]
6. Physicochemical basis for binding and voltage-dependent block of hERG channels by structurally diverse drugs.
Sanguinetti MC; Chen J; Fernandez D; Kamiya K; Mitcheson J; Sanchez-Chapula JA
Novartis Found Symp; 2005; 266():159-66; discussion 166-70. PubMed ID: 16050267
[TBL] [Abstract][Full Text] [Related]
7. APETx1, a new toxin from the sea anemone Anthopleura elegantissima, blocks voltage-gated human ether-a-go-go-related gene potassium channels.
Diochot S; Loret E; Bruhn T; Béress L; Lazdunski M
Mol Pharmacol; 2003 Jul; 64(1):59-69. PubMed ID: 12815161
[TBL] [Abstract][Full Text] [Related]
8. Computational modelling of the open-state Kv 1.5 ion channel block by bupivacaine.
Luzhkov VB; Nilsson J; Arhem P; Aqvist J
Biochim Biophys Acta; 2003 Nov; 1652(1):35-51. PubMed ID: 14580995
[TBL] [Abstract][Full Text] [Related]
9. Lidoflazine is a high affinity blocker of the HERG K(+)channel.
Ridley JM; Dooley PC; Milnes JT; Witchel HJ; Hancox JC
J Mol Cell Cardiol; 2004 May; 36(5):701-5. PubMed ID: 15135665
[TBL] [Abstract][Full Text] [Related]
10. In silico modelling--pharmacophores and hERG channel models.
Recanatini M; Cavalli A; Masetti M
Novartis Found Symp; 2005; 266():171-81; discussion 181-5. PubMed ID: 16050268
[TBL] [Abstract][Full Text] [Related]
11. A novel hypothesis for the binding mode of HERG channel blockers.
Choe H; Nah KH; Lee SN; Lee HS; Lee HS; Jo SH; Leem CH; Jang YJ
Biochem Biophys Res Commun; 2006 May; 344(1):72-8. PubMed ID: 16616004
[TBL] [Abstract][Full Text] [Related]
12. Molecular docking and molecular dynamics studies on the structure-activity relationship of fluoroquinolone for the HERG channel.
Luo F; Gu J; Chen L; Xu X
Mol Biosyst; 2014 Nov; 10(11):2863-9. PubMed ID: 25100024
[TBL] [Abstract][Full Text] [Related]
13. Modeling HERG and its interactions with drugs: recent advances in light of current potassium channel simulations.
Recanatini M; Cavalli A; Masetti M
ChemMedChem; 2008 Apr; 3(4):523-35. PubMed ID: 18224703
[TBL] [Abstract][Full Text] [Related]
14. New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies.
Farid R; Day T; Friesner RA; Pearlstein RA
Bioorg Med Chem; 2006 May; 14(9):3160-73. PubMed ID: 16413785
[TBL] [Abstract][Full Text] [Related]
15. A single amino acid difference between ether-a-go-go- related gene channel subtypes determines differential sensitivity to a small molecule activator.
Perry M; Sanguinetti MC
Mol Pharmacol; 2008 Apr; 73(4):1044-51. PubMed ID: 18162604
[TBL] [Abstract][Full Text] [Related]
16. Intracellular K+ is required for the inactivation-induced high-affinity binding of cisapride to HERG channels.
Lin J; Guo J; Gang H; Wojciechowski P; Wigle JT; Zhang S
Mol Pharmacol; 2005 Sep; 68(3):855-65. PubMed ID: 15967876
[TBL] [Abstract][Full Text] [Related]
17. S641 contributes HERG K+ channel inactivation.
Bian JS; Cui J; Melman Y; McDonald TV
Cell Biochem Biophys; 2004; 41(1):25-40. PubMed ID: 15371638
[TBL] [Abstract][Full Text] [Related]
18. The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG.
Rampe D; Murawsky MK; Grau J; Lewis EW
J Pharmacol Exp Ther; 1998 Aug; 286(2):788-93. PubMed ID: 9694935
[TBL] [Abstract][Full Text] [Related]
19. The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o.
Diaz GJ; Daniell K; Leitza ST; Martin RL; Su Z; McDermott JS; Cox BF; Gintant GA
J Pharmacol Toxicol Methods; 2004; 50(3):187-99. PubMed ID: 15519905
[TBL] [Abstract][Full Text] [Related]
20. Interaction of agitoxin2, charybdotoxin, and iberiotoxin with potassium channels: selectivity between voltage-gated and Maxi-K channels.
Gao YD; Garcia ML
Proteins; 2003 Aug; 52(2):146-54. PubMed ID: 12833539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
